search
Back to results

Fighting Social Inequality in Cardiovascular Health I (FISICH-I)

Primary Purpose

Cardiac Disease, Vascular Diseases

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Prebooking
Pictured invitation
Sponsored by
Odense University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Cardiac Disease focused on measuring Screening, Prevention, Cardiovascular, Public health

Eligibility Criteria

60 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Men aged 60-64 living in the municipalities of Funen, Silkeborg, Vejle and surrounding municipailties

Exclusion Criteria:

  • Men not aged 60-65
  • Men not living in the mentioned municipalities
  • Women

Sites / Locations

  • Nykøbing Falster Sygehus
  • Odense University Hospital
  • Region Hospital Silkeborg
  • Svendborg Sygehus
  • Vejle Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

Prebooking

Web based booking

Pictured invitation

Texted invitation

Arm Description

Participants randomised to this arm receives a prebooked appointment to screening

Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.

Participants randomised to this arm receives a pictured invitation to screening

Participants randomised to this arm receives a classical texted invitation to screening

Outcomes

Primary Outcome Measures

Attendance rate to screening
The proportion of invited attending screening

Secondary Outcome Measures

Quality of Life of invitation to screening
Quality of life measured by EurQol 5D

Full Information

First Posted
May 9, 2019
Last Updated
May 10, 2019
Sponsor
Odense University Hospital
Collaborators
Regionshospitalet Silkeborg, Vejle Hospital, Svendborg Hospital, Nykøbing Falster Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03946956
Brief Title
Fighting Social Inequality in Cardiovascular Health I
Acronym
FISICH-I
Official Title
Fighting Social Inequality in Cardiovascular Health I
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
August 1, 2017 (Actual)
Primary Completion Date
March 31, 2019 (Actual)
Study Completion Date
March 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Odense University Hospital
Collaborators
Regionshospitalet Silkeborg, Vejle Hospital, Svendborg Hospital, Nykøbing Falster Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status
Detailed Description
Background Although CVDs have decreased, they are still among the most predominant cause of morbidity and mortality in the western world, incl. Denmark, where about 420,000 people have recognized CVD symptoms. Due to an aging population, the decline has not reduced CVD admissions and healthcare costs. In Denmark, the CVD related hospital admission costs are DKK 4.6 billion and the pharmaceutical cost DKK 2.4 billion. The Danish National Board of Health has reported that CVD carries the second largest socioeconomic difference in burden of disease. Unfortunately, population-based health checks and screening for risk factors has proven not efficient. Consequently, screening of asymptomatic CVD is discussed intensively. In the investigators first unique CVD screening RCT (2008-11), the VIVA trial, they randomized more than 50.000 65-74 year old men for population-based ultrasound screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD) and hypertension. In case of positive finding, preventive medical actions were initiated. A significant reduction in overall mortality by 7% after 5 years was observed (paper submitted). Using a non-contrast CT scan, instead of the ultrasound based screening approach, has the opportunity to identify aneurysms in the entire aortic, coronary artery calcification (CAC) and arterial fibrillation, so individualized risk assessment and initiation of preventive actions on those with sign of early asymptomatic CVD is possible. The investigators therefore initiated a second trial (DANCAVAS) in 2014 randomizing 45.000 65-74 year old men with the potential of a huge beneficial effect on health, quality of life (QoL) and survival. However, screening is impaired by lower social class, and adherence to initiated prevention could be impacted as well. Consequently, they want to conduct a third RCT (FISICH) to test a number of add-ons to screening that potentially balance the benefits across socio economic groups. The perspective is to establish a clear decision foundation for public health care policy incl. benefits, cost effectiveness and impact on social inequality of alternative variants of population screening for CVD. Hypotheses The primary hypothesis is that an extensive circulatory screening and intervention programme reduces social inequality in cardiovascular health and fulfills the WHO criteria for screening. However, this reduction can be even more pronounced, if factors reducing the social selection to attend screening and adherence to preventive actions initiated are identified. Aims The aims are to Test whether prebooking and/or supplemental informative pictures of the screening session and consultation improves attendance rate in general, and particular among those with the lowest educational level, lowest income level, and psychiatric disease. Investigate whether confrontation of imaging of own arterial lesions at consultation after screening and/or an e-mail 3 and 12 months after the consultation in case of positive findings improves adherence to suggested cardiovascular preventive actions, and whether it influences quality of life, in general and especially concerning those with the lowest educational level, lowest income level, and psychiatric disease. Materials and methods In FISICH-I 20.000 60-64 year old men are randomized to the control group, while another 5.000 are randomized to the screening and intervention program for CAC, aortic and iliac aneurysms, atrial fibrillation, PAD, hypertension, diabetes and hypercholesterolaemia. There is no exclusion criteria. The screening setup is similar to DANCAVAS: A small questionnaire on life style, medical history, and the QoL a.o. will be enclosed with the invitation. Non-responders are re-invited once. The participant will be informed at attendance to the screening visit, and their consent will be obtained together with the questionnaire, weight, height, and waist circumference. The CT scan will cover the area from the mandibular bone distally to the proximal third of the femur. Calcium scores for the common carotids, coronary arteries, aorta, and common iliac, and femoral arteries will be calculated. The aorta are visualized, and the diameter is measured in ascending, arcus, descending and abdominal, and if possible in the iliac arteries. Further the heart rhythm during the CT scan is evaluated. Bilateral blood pressure will be recorded three times after 5 minutes of supine rest, and concurrently the ankle blood pressure are measured. The HbA1c and lipid parameters will be measured. Biobank blood samples are then taken, centrifuged, labelled, cooled, and stored at -80 degrees Celsius. Follow-up visit after screening If the CAC is above the median or if an aneurism of peripheral arterial disease are detected the participant is informed of the finding and its implications at a follow-up visit. At this visit, the patient will be recommended suitable prophylactic measures, including smoking cessation, walking/exercise, a lowfat diet. Additionally to start treatment with aspirin 75 mg/day and atorvastatin 40 mg/day. If an aneurism is large the patient is referred vascular surgical assessment for the repair. Otherwise, an annual check-up of the aneurism including a CT scan will be offered. If no positive findings (CAC above the median, aneurysm or PAD) are detected, the participants will be informed of the findings by e-mail or ordinary post as preferred. Independent of the above findings, the patients will be encouraged to see their GP for further assessment if potential undiagnosed hypertension (systolic blood pressure >160 mmHg), diabetes mellitus (HbA1c >48 mmol/mol), or significant isolated hypercholesterolemia (total-cholesterol >8.0 mmol/l) are observed, as possible continuous medical treatments will be better managed by the GPs. The GPs will be informed by a letter of all negative and positive results and the initiated actions. Additionally in the FISICH-I trial, four further randomizations are performed. In the written invitations to the screening examination two further randomizations are performed; prebooking versus active booking +/- addition of illustrations of the examinations during the screening session. Power calculations and Randomisations Randomisation will be performed in SPSS by providing each individual a random number from 1-20. Those numbered +16 will be invited to participate in the screening program. Those numbered 17 and 18 will be prebooked, while those numbered 19 and 20 will have to book themselves through web-booking, email or phone. Those with an equal number (18 and 20) will receive supplemental informative pictures of the screening session. In case of positive finding a new random number from 1-4 is given. Those numbered 3 and 4 will be confronted with imaging of their own arterial lesions, whilst others will receive standard information. Those with an equal number (2 and 4) will receive a SMS, e-mail and phone call 3 & 12 months after the consultation. If all groups after randomisations are equally sized,- 182 will only be additionally randomized to be remembered prescription renewal after 3 and 12 months, and 182 will only have been randomized to the standard of booking (Control group for all invited). If 12 months compliance to initiated preventive medication is 66%, then with 0.05 significance level, and 80% power, the smallest difference detectable is 15%, which seems clinical relevant. However, merged analyses adjusting for the other interventions will be performed reducing the smallest detectable difference and reveal potential synergistic combinations. Similar group comparisons will be performed for all randomized interventions. Baseline variables Age, smoking, previous or current stroke, ischemic heart disease, PAD, chronic obstructive pulmonary disease, diabetes, hypertension, use of statins, useof antithrombotics, body mass index, systolic- and diastolic blood pressure, ankle brachial index, marital status, highest educational level, personal- andin house income, psychiatric morbidity defined as any diagnosis and/or use of medications for mental illness, and QoL. Baseline and outcome variables from national registries The CPR number assigned to Danish citizens enables individual-level linkage to multiple nation-wide healthcare and administrative registries which have proved valid. Registry-based information on outpatient visits, hospitals admissions and procedures (The Danish National Patient Registry), relevant prescribed drugs dispensed (The Danish National Prescription Registry), socio economic status etc. (Registries at Statistics Denmark) and primary care service use (National Health Insurance Service Registry) will be obtained. Outcomes The primary outcomes are Attendance to screening One-year adherence to initiated lipid-lowering and/or antithrombotic medication. Secondary outcome is: 1. QoL, Statistical analysis Baseline characteristics will be analysed using conventional summary statistics. Attendance rates adjusted for invitation layout and booking-method, as well as compliance one year after initiation (def.: received a prescription 9-12 months after the consultation) adjusted for image-confrontation and post-consultation phone call are compared by logistic regression analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Disease, Vascular Diseases
Keywords
Screening, Prevention, Cardiovascular, Public health

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
2 x factorial design regarding attendance rate to cardiovacular screening
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Prebooking
Arm Type
Active Comparator
Arm Description
Participants randomised to this arm receives a prebooked appointment to screening
Arm Title
Web based booking
Arm Type
Placebo Comparator
Arm Description
Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
Arm Title
Pictured invitation
Arm Type
Active Comparator
Arm Description
Participants randomised to this arm receives a pictured invitation to screening
Arm Title
Texted invitation
Arm Type
Placebo Comparator
Arm Description
Participants randomised to this arm receives a classical texted invitation to screening
Intervention Type
Behavioral
Intervention Name(s)
Prebooking
Intervention Description
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Intervention Type
Behavioral
Intervention Name(s)
Pictured invitation
Intervention Description
Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
Primary Outcome Measure Information:
Title
Attendance rate to screening
Description
The proportion of invited attending screening
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Quality of Life of invitation to screening
Description
Quality of life measured by EurQol 5D
Time Frame
6 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men aged 60-64 living in the municipalities of Funen, Silkeborg, Vejle and surrounding municipailties Exclusion Criteria: Men not aged 60-65 Men not living in the mentioned municipalities Women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jes S Lindholt
Organizational Affiliation
Odense University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nykøbing Falster Sygehus
City
Nykøbing Falster
ZIP/Postal Code
4800
Country
Denmark
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Region Hospital Silkeborg
City
Silkeborg
ZIP/Postal Code
8600
Country
Denmark
Facility Name
Svendborg Sygehus
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Facility Name
Vejle Hospital
City
Vejle
ZIP/Postal Code
7100
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data will be analysed on Statistics Denmarks secured server

Learn more about this trial

Fighting Social Inequality in Cardiovascular Health I

We'll reach out to this number within 24 hrs